Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
A pill bottle and prescription pad on a wooden desk in a clinical office

Jun 24, 2026

[Bio USA] SK Biopharmaceuticals doubles down on AI, open innovation

SK Biopharmaceuticals is prioritizing artificial intelligence and open innovation as key strategies for future growth, particularly in drug discovery.During a recent press conference at the BIO International Convention in San Diego, CEO Lee Dong-hoon highlighted the company's commitment to leveraging AI technologies alongside traditional development methods. This shift comes on the heels of the successful launch of Xcopri, a seizure medication that has significantly boosted the company's revenue
A molecular model on a lab bench in a modern laboratory setting.

Jun 23, 2026

Genesis Workbench: A blueprint for industry AI in life sciences, powered by Databricks and NVIDIA

The Genesis Workbench represents a significant advancement in AI-driven drug discovery, integrating NVIDIA's accelerated computing with Databricks' robust data governance.This innovative platform offers a comprehensive solution for life sciences research by unifying various stages of drug discovery into a single, modular workbench. It leverages NVIDIA's BioNeMo models and the Databricks environment, allowing scientists to run AI applications directly on their sensitive data without needing to se
Minimalist illustration of a DNA helix and data flow

Jun 23, 2026

Snowflake and NVIDIA Bring Agentic AI to Life Sciences

Snowflake and NVIDIA have partnered to introduce agentic AI to the life sciences sector, enhancing the efficiency of research and development workflows.This collaboration leverages Snowflake’s data governance and orchestration capabilities alongside NVIDIA’s BioNeMo Agent Toolkit, which includes specialized AI models tailored for biological research. The integration allows pharmaceutical R&D teams to conduct complex scientific workflows directly where their data resides, thereby accelerating the
A drug compound in a petri dish in a dimly lit lab

Jun 23, 2026

The Next Frontier: AI Agents in Biology

NVIDIA's BioNeMo Agent Toolkit is poised to revolutionize drug discovery by integrating advanced AI capabilities into the life sciences sector, addressing longstanding inefficiencies in research and development.The toolkit has quickly gained traction among over 50 organizations, including major pharmaceutical companies, highlighting its importance in the biotech landscape. By leveraging agentic AI, which autonomously executes complex scientific workflows, BioNeMo aims to mitigate the high costs
Minimalist illustration of a neuron and synapse in dark colors with lime accents.

Jun 23, 2026

SK Biopharm taps Insilico in $2.5B AI CNS drug discovery deal

SK Biopharmaceuticals has entered a significant collaboration with Insilico Medicine, aimed at revolutionizing CNS drug discovery through AI technologies.The partnership, valued at over $2.5 billion, was unveiled during the BIO International Convention in San Diego. This collaboration will leverage Insilico's Pharma.AI platform alongside SK Biopharm's expertise in developing and commercializing treatments for central nervous system disorders. The deal highlights the growing trend within the biop
An open laboratory notebook on a cluttered lab bench, surrounded by papers and manuals.

Jun 23, 2026

NVIDIA tools aim to turn AI agents into lab helpers for drug discovery

NVIDIA has unveiled the BioNeMo Agent Toolkit, designed to enhance the capabilities of AI agents in drug discovery and other life sciences applications.This toolkit integrates advanced tools and libraries developed over the last decade, enabling AI agents to assist scientists in various tasks such as computational experiments, data analysis, and evidence gathering. By providing domain-specific capabilities, the BioNeMo toolkit aims to streamline workflows in biology, chemistry, genomics, and dru
A vial of drug compound on a lab bench with equipment in the background.

Jun 22, 2026

AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion

Insilico Medicine has entered a significant partnership with SK Biopharmaceuticals, valued at over $2.5 billion, aimed at advancing drug development for neuroimmune disorders.This collaboration will leverage Insilico's Pharma.AI platform for the design of new drug candidates, while SK Biopharmaceuticals will manage the later stages of development and commercialization. Initial payments to Insilico are set at $18 million, with the potential for the total deal value to reach $2.5 billion contingen
A vial of biologic drug on a laboratory countertop in a dimly lit setting.

Jun 22, 2026

France’s Bionyra Pharma launches with €143 million Series A to advance inflammatory disease biologics

Bionyra Pharma has officially launched with a significant €143 million ($165 million) Series A funding round, aimed at developing next-generation biologics for immune-mediated inflammatory diseases. The funding was co-led by Jeito Capital and Sofinnova Partners, with participation from several other investors, reflecting strong interest in innovative solutions for unmet medical needs in this field.The company, co-founded by former Sanofi R&D executive Dr. Frédéric Marrache, aims to address the s
Minimalist illustration of a brain with neuron connections

Jun 22, 2026

Insilico Announces Collaboration with SK Biopharmaceutical for AI-Powered CNS Treatment

Insilico Medicine has announced a significant collaboration with SK Biopharmaceuticals aimed at advancing AI-driven treatments for central nervous system (CNS) disorders. This partnership will leverage Insilico's Pharma.AI platform to discover novel drug candidates that will be further developed and commercialized by SK Biopharmaceuticals.According to SK Biopharmaceuticals' CEO, this collaboration marks a pivotal expansion into new therapeutic areas beyond epilepsy, building on their existing ex
A syringe filled with monoclonal antibody solution on a laboratory countertop.

Jun 22, 2026

TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma for Two Next-Generation Monoclonal and Bispecific Antibodies for Immune-Mediated Inflammatory Diseases Valued up to $985 Million

TrueLab Biopharmaceutical has entered into a significant licensing agreement with Bionyra Pharma, granting Bionyra exclusive rights to develop and commercialize two innovative antibodies aimed at treating immune-mediated inflammatory diseases. The deal could be worth up to $985 million, including milestone payments and royalties.This collaboration centers on TL-001, an anti-TL1A monoclonal antibody, and TL-003, a bispecific antibody targeting TL1A and IL-23. Bionyra is now positioned to advance
A minimalist illustration of a test tube representing drug discovery.

Jun 19, 2026

Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise

Charles River Laboratories has partnered with Lilly TuneLab to enhance its AI/ML drug discovery platform by leveraging nonclinical testing expertise.The collaboration aims to strengthen Charles River's client relationships while modernizing research and development through cutting-edge technologies. Lilly TuneLab, developed by Eli Lilly, provides a collaborative AI/ML platform that allows participating companies to utilize advanced drug discovery models based on extensive proprietary research da
A cell culture dish and pipette in a dimly lit lab setting, symbolizing biotechnology research.

Jun 19, 2026

Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers

Portal Biotechnologies has successfully closed an oversubscribed $9 million funding round, signaling robust growth in its cell engineering and drug discovery platform. This funding, led by NFX, will support the company's expansion in drug discovery workflows, AI data generation, and cell therapy manufacturing.With over 100 customers, including major players like Microsoft and Merck, Portal is gaining traction in the biotech landscape. Its innovative mechanoporation technology facilitates the del